$25m pumped into InSet
This article was originally published in Clinica
Executive Summary
InSet Technologies, a Mount Olive, New Jersey-based developer of programmable, implantable drug pumps, has raised $25m in equity financing. The round was led by Clarus Ventures. InSet will use the funds to complete the regulatory approval process for its device, which delivers medication directly to the spinal cord to provide pain relief, and to build a sales infrastructure in anticipation of the product launch.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.